Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > JDRF and Medical Research Council co-fund new research into type 1 diabetes treatments
The award funds registered healthcare professionals to complete a PhD. The scheme is available for projects focusing on many different conditions, making it incredibly competitive. A type 1 healthcare professional receiving this fellowship will help raise the profile of type 1 diabetes research and JDRF amongst researchers, healthcare professionals and government funders. We hope this will attract new funding and researchers to the field of type 1 diabetes research.
Thanks to this funding, Daniel Doherty will complete his PhD at the University of Manchester over the next three years. His project will focus on improving the outcome of islet transplants for people with type 1. His goal is for islet transplants to work better, for longer, so they can help more people with type 1.
Islets are clusters of cells in the pancreas, which contain the insulin-producing beta cells that are destroyed in type 1 diabetes.
Daniel Doherty said: “An islet transplant takes the insulin-producing cells from an organ donor’s pancreas and places them into a recipient experiencing severe type 1 diabetes. It has the potential to free patients from taking insulin.”
Islet transplants can help people with type 1 who struggle with their glucose control, but they are far from perfect. Daniel Doherty said: “At the moment islet transplantation is only available for a small group of patients as the transplants gradually decline in function and recipients need two or three transplants, limiting the total number of recipients that can benefit from the procedure.
“I am investigating how the locations that transplants are placed into interact with the insulin producing cells to see how we can make them survive longer, control blood sugar better and make it available for more people with type 1.”
Daniel will start his PhD by learning more about islets and their neighbouring cells. Islets are usually found in the pancreas, but they are transplanted into the liver because it is much easier to get to than the pancreas. Daniel will investigate why many islets don’t survive in the liver and how he could improve this.
To do this, Daniel will look closely at islets in pancreas samples donated by people without type 1. He will also figure out what types of cells are present after the islets have been separated from the rest of the pancreas. Finally, he will compare both findings with the cells that surround the islets when they reach the liver. This will help him understand how the islets interact with neighbouring cells to help them function.
Daniel hopes to use this information to create a more supportive environment for islet cells in the liver. Through this, he aims to get more islets to survive the transplant so that the people with type 1 who receive them can produce insulin more effectively.
This research will help limit the number of repeat islet transplants required, making them available for more people with type 1.
To explain his research in more detail, Daniel created this short video, which you can watch below.
Our new name, Breakthrough T1D, reflects our exclusive focus on the type 1 diabetes (T1D) community. Breakthrough T1D will continue JDRF’s journey, accelerating breakthroughs in research, breakthroughs in access to treatments, and bringing the T1D community together to help everyone make their own personal breakthroughs.
A study we helped conduct, which has just been published, reveals the most important unanswered questions about type 1 diabetes, based on the priorities of adults in the United Kingdom and Ireland. This will help guide future research to focus on what matters most to people living with the condition.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
It’s thanks to your dedication that we have funded great progress in type 1 cure, treatment and prevention research. Help us to continue our vital research.
